IMR Press / FBL / Volume 7 / Issue 4 / DOI: 10.2741/small

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Alzheimer's disease biomarkers: their value in diagnosis and clinical trials
Show Less
1 Laboratory of Molecular Neurobiology, Department of Pathology, University of Melbourne, Victoria 3010, Australia
Front. Biosci. (Landmark Ed) 2002, 7(4), 986–988;
Published: 1 April 2002

Biomarkers of Alzheimer's disease may be useful, not only for early diagnosis of the disease, but also for monitoring the progress of drug trials. A number of plasma and cerebrospinal fluid markers are reportedly altered in Alzheimer's disease. So far, no single biomarker can be used to diagnose Alzheimer's disease definitively. Nevertheless, it may eventually be possible to use several markers in combination to obtain sufficient diagnostic accuracy. However, for this to be the case, new specific biomarkers may need to be identified.

Alzheimer's disease
Back to top